Blurbs

Analysts Offer Insights on Healthcare Companies: Align Tech (ALGN), Becton Dickinson (BDX) and Biogen (BIIB)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Align Tech (ALGNResearch Report), Becton Dickinson (BDXResearch Report) and Biogen (BIIBResearch Report) with bullish sentiments.

Align Tech (ALGN)

Stifel Nicolaus analyst Jonathan Block maintained a Buy rating on Align Tech yesterday and set a price target of $625.00. The company’s shares closed last Wednesday at $545.94.

According to TipRanks.com, Block is a 5-star analyst with an average return of 17.8% and a 61.3% success rate. Block covers the Healthcare sector, focusing on stocks such as SmileDirectClub, Venus Concept, and Sonendo Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Align Tech with a $633.14 average price target, a 21.2% upside from current levels. In a report issued on January 31, Morgan Stanley also initiated coverage with a Buy rating on the stock with a $575.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Becton Dickinson (BDX)

In a report released yesterday, Rick Wise from Stifel Nicolaus maintained a Buy rating on Becton Dickinson, with a price target of $318.00. The company’s shares closed last Wednesday at $277.24.

According to TipRanks.com, Wise is a 5-star analyst with an average return of 11.1% and a 64.6% success rate. Wise covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Edwards Lifesciences, and Intuitive Surgical.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Becton Dickinson with a $286.86 average price target, representing a 3.7% upside. In a report issued on February 4, Morgan Stanley also maintained a Buy rating on the stock with a $310.00 price target.

Biogen (BIIB)

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Biogen yesterday and set a price target of $304.00. The company’s shares closed last Wednesday at $226.81, close to its 52-week low of $212.56.

According to TipRanks.com, Matteis is a 4-star analyst with an average return of 9.9% and a 45.4% success rate. Matteis covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Vertex Pharmaceuticals, and ACADIA Pharmaceuticals.

Biogen has an analyst consensus of Moderate Buy, with a price target consensus of $264.78, which is a 18.0% upside from current levels. In a report issued on February 4, Cowen & Co. also maintained a Buy rating on the stock with a $285.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ALGN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
Videos

Latest News Feed